Company intelligence / Profile preview

Lepzi Biotechnology

Richmond, British Columbia, Canadalepzi.com ↗

Ownership: Private
Employees: ~50
Development stage: Commercial

Overview

Lepzi Biotechnology develops and markets rapid point-of-care diagnostic tests for women’s health, cardiovascular/pulmonary diseases, infectious disease/inflammation, tumor markers, and drug abuse. Their LEPZI® PLGF test has been featured in peer-reviewed studies for preeclampsia screening. The company offers a broad portfolio of CE-marked or equivalent commercialized products used globally at the near-patient setting.

Therapeutic areas: Infectious DiseasesCardiovascularWomen's Health
Modalities: DeviceDiagnostic test (in vitro diagnostic)
Industry: Protein Biomarker Diagnostics

Partnerships

Una Health – collaboration on the Lepzi PLGF study with Action on Pre-eclampsia UK/APEC

Beyond the preview

Go deeper on Lepzi Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lepzi Biotechnology.

Explore the full profile